CMTX-101: IV Treatment of P. aeruginosa in Combination with Inhaled Antibiotics
Trial Objectives
People with cystic fibrosis (CF) are more vulnerable to a wide variety of bacterial infections in their lungs. One of these bacteria, Pseudomonas aeruginosa, can cause infections that decrease lung function over time. Researchers are evaluating a new therapy that may help people with CF more effectively clear these infections.
Pseudomonas bacteria can become resistant to antibiotic treatment in the lungs by forming biofilms, a protective structure that shields the bacteria from both the body’s own immune system and treatment drugs. This clinical trial is evaluating CMTX-101, an investigational drug that is intended to break down these biofilms and help treat these difficult-to-clear infections when given with antibiotics.
Who Can Participate
Adults who are diagnosed with cystic fibrosis, are chronically infected with P. aeruginosa and are currently receiving inhaled tobramycin alone, inhaled aztreonam alone or combined antibiotic therapy. Participants must have an FEV1 greater than 50%.
Age: 18+ Gender: Any
Estimated Time Commitment
Seven clinic visits over approximately 35 days. Total study duration includes up to 60 days of screening.
Payment & Reimbursement
Payment: Provided
Travel Reimbursement: Available
Trial Location
National Jewish Main Campus, Denver, CO
Trial Sponsors
Clarametyx Biosciences
Principal Investigators
Jerry A. Nick, MD
Co-Investigators
-
Jane E. Gross, MD, PhD
-
Jennifer L. Taylor-Cousar, MD, MSCS